Trial · NCT05331144
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
NCT05331144, Phase 2, Active not recruiting, Rong Zhang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study). Trials, record NCT05331144. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05331144
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
- NCT number
- NCT05331144
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 180 participants, estimated
- Lead sponsor
- Rong Zhang
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
- Interventions
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
- First posted
- 2022-04-15
- Last updated
- 2026-07-21
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) | Baseline, 24 months | Brain Aβ will be measured by annual change of amyloid mean cortical standardized uptake value ratio (SUVR) with positron emission tomography (PET). |
| Secondary | Change From Baseline in Brain Tau Deposition | Baseline, 24 months | Brain Tau Deposition will be measured by tau temporal meta-ROI composite with positron emission tomography (PET). |
| Secondary | Change From Baseline in regional Cerebral Blood Flow (CBF) | Baseline, 12 months, 24 months | Regional CBF will be measured by MRI using arterial spin labeling. |
| Secondary | Change From Baseline in global Cerebral Blood Flow (CBF) | Baseline, 12 months, 24 months | Global CBF will be measured by PC-MRI and 2D color-coded duplex ultrasonography. |
| Secondary | Change From Baseline in Arterial Stiffness | Baseline, 12months, 4 months | Central arterial stiffness (pulse wave velocity and carotid β-stiffness index) will be measured by artery applanation tonometry. |
| Secondary | Change From Baseline in Amplitude of Low Frequency Fluctuations of Blood-Oxygen-Level-Dependent Signal (BOLD ALFF) | Baseline, 12 months, 24 months | BOLD ALFF will be measured by resting state functional MRI (rs-fMRI). |
| Secondary | Change From Baseline in White Matter Hyperintensity Volume | Baseline, 12 months, 24 months | White matter hyperintensity volume will be measured by MRI using 3D T2 FLAIR sequence . |
| Secondary | Change From Baseline in Brain Neural Network Connectivity | Baseline, 12 months, 24 months | Brain neural network connectivity will be measured by rs-fMRI. |
| Secondary | Change From Baseline in Neurocognitive Function | Baseline, 12 months, 24 months | A composite z score will be obtained by conversion of individual test scores of the Preclinical Alzheimer Cognitive Composite (PACC) and the NIH Toolbox Cognition Battery to standardized z scores, then averaged to assess changes in global cognitive function. Domain-specific z scores will be used to assess specific domains of cognitive function (i.e., memory, executive function, language etc.). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AG076660 | Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT-study) | ZHANG, RONG; VONGPATANASIN, WANPEN; ZHU, DAVID C | UT SOUTHWESTERN MEDICAL CENTER | NATIONAL INSTITUTE ON AGING | 2022 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05331144
GET https://conductscience.org/api/trials/v1/NCT05331144/registered